Small molecule · Agonist · developed by Merz Pharmaceuticals, Llc
Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier and is converted to dopamine in the brain, where it stimulates dopaminergic receptors. It is administered with carbidopa, a decarboxylase inhibitor that acts peripherally.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07614126 | N/A | CTNNB1 | Recruiting | PTCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CTNNB1L-DOPA
Updated Oct 25, 2026.